TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Real Time 3D Imaging and Surrogate Bone Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects to be included in this protocol will be adult males and females of all races and socioeconomic status meeting the following criteria:~* Primary, unilateral Total hip arthroplasty (THA)~* 18 to 85 years old at time of surgery~* Able to get a pre- and post-operative CT scan at the Cleveland Clinic Main Campus at least 10 days prior to surgery~Exclusion Criteria:~* Significant metal in the joint that results in metal artifact on the pre--operative CT scan, thereby compromising the ability to visualize the acetabulum on the pre-operative simulator.~* Pregnancy~* Incarceration~* Condition deemed by physician or medical staff to be non-conducive to patient's ability to complete the study, or a potential risk to the patient's health and well-being.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 3D imaging, surrogate bone model (Type: EXPERIMENTAL): 3D imaging \& surrogate bone model
- Standard of Care Preoperative Imaging (Type: NO_INTERVENTION): Patients receiving standard of care preoperative planning prior to total hip arthroplasty.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).~* Radiographically measurable or evaluable disease.~* Life expectancy of at least 12 weeks.~* Tumor without activating driver mutations for which there is available therapy (eg, tumor without mutations in epidermal growth factor receptor or anaplastic lymphoma).~* An modified Glasgow Prognostic Score (mGPS) of 1 or 2 as defined below:~  * Criteria:~    * C-reactive protein \>10 mg/L AND albumin ≥35 g/L; Score = 1~   * C-reactive protein \>10 mg L AND albumin \<35 g/L; Score = 2~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.~* Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit.~Exclusion Criteria:~* Squamous or mixed histology (eg, adenosquamous) NSCLC~* Previous systemic therapy for advanced or metastatic disease.~* Known active central nervous system (CNS) metastases.~* Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy without sponsor approval.~* Current uncontrolled cardiac disease such as angina or myocardial infarction, congestive heart failure including New York Heart Association functional classification of 3, or arrhythmia requiring treatment.~* Uncontrolled concomitant medical conditions, including, but not limited to, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib plus Pemetrexed/Cisplatin (Type: EXPERIMENTAL): None
- Placebo plus Pemetrexed/Cisplatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• All children registered during pregnancy will be eligible for the study provided they have not yet received BCG at the date of the home visit.~Exclusion Criteria:~* Children born outside the cluster, and returning more than 72 hours after the delivery~* Children that the nurse evaluates to die within the next 24 hours.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: t

Study Arms:
- Intervention: BCG and OPV at home visits (Type: ACTIVE_COMPARATOR): Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
- Control: No vaccines at home visits (Type: NO_INTERVENTION): For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Secur-Fit Advanced Outcomes Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has signed an Institutional Review Board (IRB)/Ethics Committee (EC) approved, study specific Informed Patient Consent Form.~* Patient is a male or non-pregnant female, skeletally mature and age 21-75 years at time of study device implantation.~* Patient has a diagnosis of Non-Inflammatory Degenerative Joint Disease.~* Patient is a candidate for primary total hip arthroplasty.~* Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations and rehabilitation.~Exclusion Criteria:~* Patient has previously undergone open surgical intervention on the operative hip.~* Patient has a prior femoral fracture, with or without deformity, on the operative side.~* Patient has an existing total hip replacement on the contralateral side.~* Patient requires simultaneous bilateral total hip replacement.~* Patient has a Body Mass Index (BMI) \> 45.~* Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.~* Patient has a neuromuscular or neurosensory deficiency that would create an unacceptable risk of instability, prosthesis fixation failure or complications in postoperative care, or which limits the ability to evaluate the safety and efficacy of the device.~* Patient has bone stock that is inadequate for support or fixation of the prosthesis, or is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's disease) leading to progressive bone deterioration.~* Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days).~* Patient has a known sensitivity to device materials.~* Patient is a prisoner.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Secur-Fit Advanced (Type: OTHER): Secur-Fit Advanced Hip Stem

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Early Systemic Sclerosis by Bosentan

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Early systemic sclerosis~Exclusion Criteria:~* Age \> 70 or \< 18~* Pregnancy~* Nursing~* HIV~* Hb \< 8.5 g/l~* Systolic blood pressure \< 85 mmHg~* Lack of compliance~* Liver disease~* Hypersensitivity to bosentan~* Concurrent us of glibenclamide, ciclosporine A or tacrolimus -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Newly diagnosed cases with diagnostic criteria for EoE (ie at least 15 eosinophils per high power field (Magnification 10 times 40 = x400) in any field of view in any esophageal biopsy and concurrent symptoms of esophageal dysfunction mainly dysphagia.~* Women of childbearing age may participate provided that the pregnancy is not planned , and that contraceptive use during therapy. The investigator will arrange a free pregnancy test must be performed within 1 week before treatment and be negative.~* Participation requires oral and written informed and signed consent form (see patient information and consent forms).~Exclusion Criteria:~* Local infection of the pharynx or esophagus , such as fungal, bacterial or viral infection~* Active or latent tuberculosis in respiratory tract~* Recent history of major trauma or major surgery~* Recent significant infection or other physical stress~* Signs or suspicion of dehydration~* History of injury, illness or surgery in the adrenals or pituitary~* Pharynx or esophagussurgery or other trauma in the esophagus (incl. foreign body with a sharp object ) where healing has not taken place. (in case of doubt to be assessed by esophago - gastroscopy.~* Planned elective surgery during treatment~* Pregnancy, ongoing or planned~* Women of childbearing potential not using preventives during the study period~* Glaucoma~* Hypersensitivity to any component in the treatments~* Systemic or local steroid treatment last 4 months~* Contraindication to steroid therapy ( immune deficiency or suppression , stomach ulcers, diabetes)~* Medications that affect oesophageal motility (cisapride, erythromycin ) during the treatment period .~* PPIs during or up to 2 weeks before the treatment period~* Other cause of dysphagia (cancer, connective tissue disease , neurological disease )~* Volunteer who can not consent to the study or complete a questionnaire

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mometasone furoat (Type: EXPERIMENTAL): Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
- Placebo spray (Type: PLACEBO_COMPARATOR): Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects will be at least 18 years of age without gender or ethnic restrictions.~2. Severe accidental TBI defined as the lowest post-resuscitation GCS \< 8 prior to administration of sedatives or paralytics.~3. Eligibility for MRI per routine screening checklist.~Exclusion Criteria:~1. History of neurosurgical intervention, excluding the placement of ventriculostomy shunt~2. History of a prior known brain injury with associated loss of consciousness.~3. History of a known neurological disorder prior to qualifying injury.~4. History of psychiatric disorder.~5. History of diabetes or current unstable serum glucose level.~6. Renal insufficiency or known history of kidney disease.~7. Known contraindication to MRI such as, pacemaker, pregnancy, and/or other non-MR compatible implanted device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): 13C Magnetic resonance (MR) spectroscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FilmArray Pneumonia Panel for Antimicrobial Treatment of HAP/VAP in Intensive Care Units

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 19 years or older~2. Diagnosed with hospital-acquired or ventilator-associated pneumonia and being treated in an intensive care unit~3. Patient or his/her legal proxy agrees to participate and is able to provide informed consent~Exclusion Criteria:~1. Has been treated with antibiotic for HAP/VAP for 24 hr or longer~2. Requires antibiotic treatment for indications other than HAP/VAP~3. Bacteria has been isolated from respiratory specimens within 7 days prior to screening~4. Immunocompromised host whose major differential diagnosis includes Pneumocystis jirovecii or cytomegalovirus pneumonia~5. Expected to die within 2 days since screening due to underlying disease~6. Has an advance directive against mechanical ventilation or cardiopulmonary resuscitation~7. Does not want to participate or unable to provide consent~8. Determined to be unfit by the study investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): Respiratory specimens from the subjects are tested by the FilmArray Pneumonia panel and the results are reported via an electronic health record system. Treating physicians may adjust empirical antibiotic regimens with assistance from the guidelines formulated by the study investigators. Other microbiologic tests, including cultures, are performed as per routine practice.
- Control (Type: NO_INTERVENTION): Microbiologic tests, including cultures, are performed as per routine practice. No intervention is made on the antimicrobial treatment in the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Cyanoacrylate Tissue Adhesive and Suture for Closure of Cardiac Device Pockets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for implantation of a pacemaker or ICD in the deltopectoral region at Mayo Clinic Hospital in Phoenix.~Exclusion Criteria:~* Allergy to one of the closure materials.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adhesive (Type: EXPERIMENTAL): Cyanoacrylate tissue adhesive.
- Suture (Type: ACTIVE_COMPARATOR): Polyglactin 910 suture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with open angle glaucoma at the University of Pittsburgh Medical Center (UPMC) Glaucoma Clinic.~* Able to provide written informed consent to participate.~* Must be between the ages of 18 - 95.~* Patients in which further IOP lowering by SLT is necessary in the opinion of the treating physician.~Exclusion Criteria:~* Patients with eye surgery in the prior six months.~* Patients with prior or current use of topical or systemic corticosteroids or NSAIDs.~* Patients with pre-existing anterior chamber inflammation.~* Patients with known sensitivity to any of the study medications.~* Due to the age range and the disease entity, special patient populations such as children or pregnant women will not be enrolled in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between the ages of 18 and 65 years with a confirmed diagnosis of pulmonary fibrosis secondary to systemic sclerosis~* Both men and women must be willing to use two forms of contraception. Additional information regarding this requirement is available at screening~Exclusion Criteria:~* Certain medical conditions may exclude patients from participation.~* Should not have participated in another clinical study within 4 weeks of study start~* Smokers are not eligible for participation~* Blood loss of donation of 400 mL or more within 2 months of study start~* Pregnant women or women who are breast feeding~* Past medical history of clinically significant ECG abnormalities~* Connective tissue disorders other than systemic sclerosis.~* Active infection or history of systemic parasitic infection~* History of immunodeficiency diseases, including a positive HIV test result~* History of drug or alcohol abuse within 12 months of study start~* Any condition that may compromise patient safety~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): QAX576
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using any conditioning regimen~* Experienced new onset of at least one of the following respiratory symptoms ≤5 days before study Day 1:~Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation, hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT~* A positive RSV diagnostic test~* Provided written informed consent~Exclusion Criteria:~* Is intubated and requires invasive ventilation~* Has received any investigational RSV vaccine after HSCT, or has received any monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation~* Treatment with intravenous ribavirin~* Positive for test for influenza or parainfluenza~* Significant untreated bacteraemia or fungaemia~* Significant untreated bacterial, fungal, or viral pneumonia~* Precluded from participating as a result of treatment with another investigational drug or participation in another clinical trial~* Other disease or condition which would preclude the subject's participation in a clinical trial~* Is receiving an antiretroviral protease inhibitor~* Has chronic, active hepatitis infection~* Known alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active + SoC (Type: EXPERIMENTAL): Daily doses of PC786 for 3 days + SoC
- Placebo + SoC (Type: PLACEBO_COMPARATOR): Daily doses of Placebo for 3 days + SoC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyponatremia and Myometrium Contractility. An Invitro Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy at term~Exclusion Criteria:~* Preeclampsia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility